株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界の医薬品受託製造市場:2017年〜2027年

Pharmaceutical Contract Manufacturing Market 2017-2027: Active Ingredient (API) and Finished Dose Formulation (FDF), Generic APIs, HPAPIs, Solid Dosages, Injectable Dosages

発行 Visiongain Ltd 商品コード 214197
出版日 ページ情報 英文 235 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=143.68円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
世界の医薬品受託製造市場:2017年〜2027年 Pharmaceutical Contract Manufacturing Market 2017-2027: Active Ingredient (API) and Finished Dose Formulation (FDF), Generic APIs, HPAPIs, Solid Dosages, Injectable Dosages
出版日: 2017年02月02日 ページ情報: 英文 235 Pages
概要

世界の医薬品受託製造市場は、2021年には880億米ドルに達し、CAGR (複合年間成長率) で6.4%の成長、2027年には1,240億米ドルに達し、CAGR (複合年間成長率) で5.7%の成長が予測されています。

当レポートでは、世界の医薬品受託製造市場について調査分析し、市場予測、二次市場の予測、主要国の収益予測、主要企業など、体系的な情報を提供しています。

第1章 レポート概要

第2章 医薬品受託製造:イントロダクション

  • 医薬品受託製造とは
  • 医薬品市場におけるアウトソーシングのメリット
  • 医薬品受託製造サービス
  • 戦略と戦術:アウトソーシングの重要性
  • 医薬品受託製造の動向
  • 医薬品受託製造:市場区分

第3章 医薬品受託製造:世界市場

  • 医薬品受託製造市場:実績
  • 医薬品受託製造:市場全体の予測

第4章 API (原薬) 受託製造サービス二次市場

  • API受託製造二次市場
  • API受託製造二次市場:見通しと予測
  • ジェネリックAPI受託製造二次市場
  • HPAPI (高活性原薬) 受託製造二次市場

第5章 FDF (最終製剤) 受託製造サービス二次市場

  • FDF受託製造二次市場
  • FDF受託製造二次市場の予測
  • 固体製剤受託製造二次市場
  • 注射用製剤受託製造二次市場

第6章 医薬品受託製造:主要国市場

  • 医薬品受託製造の主要国市場
  • 米国の医薬品受託製造市場の予測
  • EUの医薬品受託製造の見通し
  • 日本の医薬品受託製造

第7章 医薬品受託製造:主な新興市場

  • 新興国の医薬品受託製造
  • 中国の医薬品受託製造サービスの需要
  • インド:強いインフラ設備と専門技術を有するCMO
  • ブラジル:受託製造の見通し
  • ロシアの医薬品受託製造市場
  • 韓国:政府支援の拡大

第8章 医薬品受託製造市場における主要企業

  • 主な受託製造機関 (CMO)
  • Catalent
  • Lonza
  • Evonik Degussa
  • DPx Holdings - DSM and Patheon
  • Teva
  • Boehringer Ingelheim BioXcellence
  • Famar
  • Fareva
  • Vetter Pharma
  • Mylan

第9章 医薬品受託製造産業の動向:CMOの観点からの定性分析

  • 強み・弱み
  • 機会・脅威
  • STEP分析
  • CMOに影響を与える創薬の動向
  • CMOの拡大 (今後10年間)
  • 製造工程の発展

第10章 医薬品受託製造産業の動向:クライアントの観点からの定性分析

  • 強み・弱み
  • 機会・脅威
  • アウトソーシングの意思決定における重要な側面
  • アウトソーシング提携の動向

第11章 結論

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: PHA0167

The pharmaceutical contract manufacturing market is expected to grow at a CAGR of 6.4% in the first half of the forecast period and CAGR of 5.7% in the second half of the forecast period. The market is estimated at $88bn in 2021 and $124bn in 2027.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 235-page report you will receive 82 tables and 61 figures- all unavailable elsewhere.

The 235-page report provides clear detailed insight into the pharmaceutical contract manufacturing market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

  • Global Pharmaceutical Contract Manufacturing Market forecasts from 2017-2027
  • Submarket forecasts at world level, from 2017-2027:
    • Active pharmaceutical ingredients (APIs) , with sub forecasts for generic APIs, high potency active pharma ingredients (HPAPIs) and other products
    • Finished dosage formulations (FDFs) , with sub forecasts for solid dose forms, injectable dosages and other dosage types
    • Other applications of outsourced production
    • other related services
  • Revenue forecasts from 2017-2027, for 12 countries:
    • United States (US)
    • EU5: Germany, France, the UK, Italy and Spain
    • BRIC: Brazil, Russia, India and China
    • South Korea
    • Japan
  • Assessment of selected leading companiesthat hold major market shares in the pharmaceutical contract manufacturing industry
  • Qualitative Analysis from a CMO Perspective 2016-2027
  • Qualitative Analysis from a Client Perspective 2016-2027

Visiongain's study is intended for anyone requiring commercial analyses for the Pharmaceutical Contract Manufacturing Market. You find data, trends and predictions.

Buy our report today Pharmaceutical Contract Manufacturing Market 2017-2027: Active Ingredient (API) and Finished Dose Formulation (FDF), Generic APIs, HPAPIs, Solid Dosages, Injectable Dosages.

visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Global Pharmaceutical Contract Manufacturing Market Segmentation
  • 1.2. Global Pharmaceutical Contract Manufacturing Market Overview
  • 1.3. Why You Should Read This Report
  • 1.4. How This Report Delivers
  • 1.5. Key Questions Answered by This Analytical Report
  • 1.6. Who is This Report For?
  • 1.7. Methodology
  • 1.8. Frequently Asked Questions (FAQ)
  • 1.9. Associated Visiongain Reports
  • 1.10. About Visiongain

2. Introduction to Pharmaceutical Contract Manufacturing

  • 2.1. What is Pharmaceutical Contract Manufacturing?
  • 2.2. The Benefits of Outsourcing in the Pharmaceutical Market
  • 2.3. Pharmaceutical Contract Manufacturing Services
  • 2.4. Strategy and Tactics: The Importance of Outsourcing Wisely
  • 2.5. Trends in Contract Manufacturing, 2016-2027
  • 2.6. Pharmaceutical Contract Manufacturing: Market Segmentation

3. Pharmaceutical Contract Manufacturing: World Market 2015-2027

  • 3.1. Pharmaceutical Contract Manufacturing Market: Historical Performance 2012-2016
    • 3.1.1. Contract Manufacturing is the Most Mature Pharma Outsourcing Sector
    • 3.1.2. The Pharma Contract Manufacturing Market by Sector 2016
  • 3.2. Pharma Contract Manufacturing: Overall Market Forecast 2015-2027
    • 3.2.1. Changing Submarket Shares by Segment 2015-2027
    • 3.2.2. Drivers for Growth in the Contract Manufacturing Market to 2027
    • 3.2.3. Generics: A Driver or Restraint?
    • 3.2.4. Other Contract Manufacturing Services Submarket: Outlook and Forecast 2016
      • 3.2.4.1. Increasing Demand for Formulation Development Services

4. The Contract API Manufacturing Services Submarket 2015-2027

  • 4.1. The Contract API Manufacturing Submarket, 2016
    • 4.1.1. Chemical APIs Will Experience Resurgence After the Shift of Focus to Biological APIs
    • 4.1.2. The API Manufacturing Submarket by Sector, 2016
  • 4.2. The Contract API Manufacturing Submarket: Outlook and Forecast 2015-2027
    • 4.2.1. Drivers for Growth in the API Submarket to 2027
    • 4.2.2. The Potential for Microreactors in Commercial Manufacturing to 2027
    • 4.2.3. How Will New EU Regulations Impact the API Manufacturing Submarket?
    • 4.2.4. Contract API Manufacturing Submarket Restraint 2016-2027
      • 4.2.4.1. Backwards Integration for Generics Manufacturers
  • 4.3. The Contract Generic API Manufacturing Submarket 2015-2027
    • 4.3.1. The Contract Generic API Manufacturing Submarket Forecast 2015-2027
    • 4.3.2. The Contract Generic API Manufacturing Submarket Drivers and Restraints to 2027
      • 4.3.2.1. The US Generic Drug User Fee Act and API Manufacturing
  • 4.4. The Contract HPAPI Manufacturing Submarket 2015-2027
    • 4.4.1. Challenges and Opportunities in High Containment Manufacturing
    • 4.4.2. Company Investment into HPAPI Manufacturing Facilities: Growth Increases in the HPAPI Manufacturing Sector
    • 4.4.3. The Contract HPAPI Manufacturing Submarket Forecast 2015-2027
    • 4.4.4. The Contract HPAPI Manufacturing Submarket Drivers and Restraints to 2027

5. The Contract FDF Manufacturing Services Submarket 2015-2027

  • 5.1. The Contract FDF Manufacturing Submarket, 2016
    • 5.1.1. Solid Dosage Manufacturing Leads the Market
    • 5.1.2. CMOs Report High Demand for Softgel Formulations
  • 5.2. The Contract FDF Manufacturing Submarket Forecast 2015-2027
    • 5.2.1. Complex Molecule Manufacturing Will Drive Growth to 2027
    • 5.2.2. What Will Restrain Growth in FDF Outsourcing?
  • 5.3. The Contract Solid Dosage Manufacturing Submarket 2015-2027
    • 5.3.1. How Will Revenue for Solid Dosage Manufacturing Grow to 2027?
    • 5.3.2. The Solid Dosage Manufacturing Submarket Drivers and Restraints 2016-2027
      • 5.3.2.1. Will Product Reformulation Drive Growth to 2027?
  • 5.4. The Contract Injectable Dosage Manufacturing Submarket 2015-2027
    • 5.4.1. The Contract Injectable Dosage Manufacturing Submarket Forecast 2015-2027
      • 5.4.1.1. Drug Shortages Offer Opportunity to CMOs in the Short-Term
    • 5.4.2. Demand for Biopharma Manufacturing Will Drive Growth 2016-2027
      • 5.4.2.1. Interest in Antibody-Drug Conjugate Development Is Growing
      • 5.4.2.2. Challenges in Manufacturing Antibody-Drug Conjugates
    • 5.4.3. Lyophilisation and Aseptic Filling Demand Will Rise
      • 5.4.3.1. Will Spray Drying Replace Lyophilisation in FDF Manufacturing?

6. Leading National Markets for Pharmaceutical Contract Manufacturing 2015-2027

  • 6.1. Leading National Markets for Pharmaceutical Contract Manufacturing, 2016
    • 6.1.1. Challenges in Assessing the Market: Supply versus Demand
    • 6.1.2. Leading National Pharmaceutical Contract Manufacturing Markets: Revenue Forecasts 2015-2027
    • 6.1.3. Pharmaceutical Manufacturing in the US: Regulatory Oversight 2014-2016
    • 6.1.4. Controlling Foreign Manufacturing Sites
    • 6.1.5. What Impact Will the GDUFA 2012 Have on Foreign Manufacturing?
    • 6.1.6. Outsourcing and US Manufacturing Regulations
    • 6.1.7. Increased Demand for Domestic API Manufacturing?
  • 6.2. The US Contract Manufacturing Market Forecast 2015-2027
  • 6.3. Outlook for Pharmaceutical Contract Manufacturing in the EU
    • 6.3.1. The EU is the Leading Destination for Pharmaceutical Contract Manufacturing
    • 6.3.2. Regulatory Aspects of Pharma Manufacturing in the EU
      • 6.3.2.1. The European Commission Amends Annex 16
      • 6.3.2.2. The Falsified Medicine Directive: Controlling API Imports
    • 6.3.3. Biopharma Manufacturing Demand Will Rise to 2027
    • 6.3.4. The EU Contract Manufacturing Market Forecast 2015-2027
    • 6.3.5. Germany: The Leading EU Destination for API and FDF Manufacturing
      • 6.3.5.1. Demand for Contract Manufacturing in Germany: Revenue Forecast 2015-2027
    • 6.3.6. CMOs Account for a Third of Manufacturing Sites in France
      • 6.3.6.1. French Pharma Contract Manufacturing Market Forecast 2015-2027
    • 6.3.7. Italy: Strong API Manufacturing Traditions
      • 6.3.7.1. Revenue Forecast for the Italian Pharma Contract Manufacturing Market 2015-2027
    • 6.3.8. Spain: How Will Demand for Manufacturing Services Grow to 2027?
    • 6.3.9. UK: Pharmaceutical Contract Manufacturing Market Forecast 2015-2027
  • 6.4. Pharma Contract Manufacturing in Japan to 2027
    • 6.4.1. Pharmaceutical Manufacturing Regulations in Japan
      • 6.4.1.1. The Pharmaceutical Affairs Law
    • 6.4.2. Greater API Outsourcing to Drive Japanese Market Growth to 2027 In Spite of Currency Devaluation Weakening the Economy

7. Leading Emerging Markets for Pharmaceutical Contract Manufacturing 2015-2027

  • 7.1. Pharmaceutical Contract Manufacturing in Developing Countries
    • 7.1.1. Outsourcing to Emerging National Markets from Developed Markets
      • 7.1.1.1. Demand Will Increase for Services in India and China
    • 7.1.2. Domestic Demand for Pharmaceutical Contract Manufacturing Services
    • 7.1.3. Pharmaceutical Contract Manufacturing: Leading Emerging National Market Forecasts 2015-2027
  • 7.2. Chinese Demand for Pharma Contract Manufacturing Services 2015-2027
    • 7.2.1. Improved Manufacturing Regulations in China
      • 7.2.1.1. New Regulations for Excipients and Guidance for API Manufacturing 2012-2013
      • 7.2.1.2. What Are the Consequences to Stricter Manufacturing Regulations in China?
    • 7.2.2. Chinese CMOs Are Investing in Biopharma Manufacturing
    • 7.2.3. China Pharma Contract Manufacturing Market Forecast 2015-2027
  • 7.3. India: CMOs with Strong Infrastructure and Growing Expertise
    • 7.3.1. Regulatory Outlook for Indian Pharma Manufacturing
      • 7.3.1.1. Stricter Quality Standards to Ensure Compliance with EU Rules
    • 7.3.2. Domestic Manufacturing Dominates the Indian Pharma Market
    • 7.3.3. Demand for Contract Manufacturing in India: Market Forecast 2015-2027
  • 7.4. Brazil: Contract Manufacturing Outlook 2015-2027
    • 7.4.1. Pharmaceutical Manufacturing Regulations in Brazil
      • 7.4.1.1. New Guidelines and Regulations Proposed 2012-2013
    • 7.4.2. Brazil Imports Most of its APIs
    • 7.4.3. Brazil: Pharma Contract Manufacturing Market Forecast 2015-2027
  • 7.5. The Russian Pharma Contract Manufacturing Market 2015-2027
    • 7.5.1. Pharma Manufacturing Regulations in Russia
      • 7.5.1.1. Compliance with GMP in Russia
    • 7.5.2. How Will Demand for Contract Manufacturing Grow in Russia to 2027?
  • 7.6. South Korea: Government Supported Growth
    • 7.6.1. South Korea: Strict GMP Regulations
    • 7.6.2. South Korea: Pharma Contract Manufacturing Market Forecast 2015-2027

8. Leading Companies in the Pharmaceutical Contract Manufacturing Market

  • 8.1. Leading CMOs in the Pharmaceutical Contract Manufacturing Market
  • 8.2. Catalent: Leading CMO
    • 8.2.1. Multiple Expansions and Increased Focus on Biologic Manufacturing
  • 8.3. Lonza: Potential to Lead in ADC Manufacturing
    • 8.3.1. Lonza: Expanding its Capacities to Meet Customer Demand for Biologic Manufacturing
  • 8.4. Evonik Degussa: Specialising in Small Molecules
    • 8.4.1. Developments at Evonik Degussa
  • 8.5. DPx Holdings - DSM and Patheon: Recent Merger Has Strengthened Their Position
    • 8.5.1. Increasing Capacity Tactically and Expanding Worldwide
  • 8.6. Teva: The World's Largest API Manufacturer
    • 8.6.1. Will Teva Expand into Emerging Markets?
  • 8.7. Boehringer Ingelheim BioXcellence: Boehringer's Biopharma Manufacturing Division
    • 8.7.1. Adding New Services for Growth
  • 8.8. Famar: A Possible Candidate for Acquisition
  • 8.9. Fareva: A Strategic Shift from Acquisition to Increase in Capacity
  • 8.10. Vetter Pharma: Specialists in Aseptic Filling, Lyophilisation and Siliconisation
    • 8.10.1. Vetter's Growth: Increasing in Capacity and Market Expansion
  • 8.11. Mylan: A World Leader in Generics Manufacturing

9. Pharmaceutical Contract Manufacturing Industry Trends: Qualitative Analysis from a CMO Perspective 2016-2027

  • 9.1. Pharma Contract Manufacturing Market: Strengths and Weaknesses from a CMO Perspective 2016-2027
  • 9.2. Pharma Contract Manufacturing Market: Opportunities and Threats from a CMO Perspective 2016-2027
  • 9.3. Pharma Contract Manufacturing Market: STEP Analysis 2016-2027
    • 9.3.1. Social Factors
    • 9.3.2. New Technologies Will Drive Market Growth to 2027
      • 9.3.2.1. Advantages of Single-Use Technologies in Biopharma Manufacturing
      • 9.3.2.2. Green Technology in Contract Manufacturing
      • 9.3.2.3. Drug Delivery Trends and CMOs
      • 9.3.2.4. Biologics Are Causing Increased Demand for Lyophilisation
      • 9.3.2.5. Improving Solubility and Stability for Small Molecules
      • 9.3.2.6. Spray Drying as an Advantageous Alternative to Lyophilisation
      • 9.3.2.7. Hot-Melt Extrusion: A Niche Opportunity
    • 9.3.3. Economic Pressures
      • 9.3.3.1. Developed-Market CMOs Facing Competition from Emerging Markets
    • 9.3.4. Political Issues
      • 9.3.4.1. How Will Regulatory Developments Affect CMOs?
  • 9.4. Trends in Drug Development Affecting CMOs to 2027
    • 9.4.1. Orphan Drug Development: Smaller Manufacturing Capacities
    • 9.4.2. Complex Biologics: Interest in ADCs is Increasing
    • 9.4.3. How Will Biosimilar Market Growth Affect CMOs?
    • 9.4.4. The Future of Small Molecule Outsourcing
  • 9.5. How Will CMOs Expand in the Coming 10 Years?
    • 9.5.1. CMO Consolidation Will Increase
    • 9.5.2. There Will Be More Manufacturing Facilities Available for Acquisition
  • 9.6. Developments in the Manufacturing Process 2016-2027
    • 9.6.1. Rising Interest from Companies in Quality by Design (QbD)
    • 9.6.2. A Move Towards Continuous Manufacturing

10. Pharmaceutical Contract Manufacturing Trends: Qualitative Analysis of the Pharmaceutical Contract Manufacturing Market from a Client Perspective 2016-2027

  • 10.1. Pharma Contract Manufacturing Market: Strengths and Weaknesses from a Client Perspective 2016-2027
  • 10.2. Pharma Contract Manufacturing Market: Opportunities and Threats from a Client Perspective 2016-2027
  • 10.3. Important Aspects of the Outsourcing Decision
    • 10.3.1. What Factors Will Influence CMO Selection?
    • 10.3.2. CMO-Pharma Partnering Models
    • 10.3.3. Strategic Partnering
    • 10.3.4. Selecting a Local CMO vs. Offshoring
    • 10.3.5. CMOs in Emerging Markets
    • 10.3.6. Good Communication is Vital for Success
    • 10.3.7. Ensuring Protection in Intellectual Property and Tech Transfer
    • 10.3.8. Regulatory Compliance is a Key Deciding Factor for Pharma Clients
      • 10.3.8.1. Regulatory Bodies and Outsourcing
      • 10.3.8.2. Quality Agreement
      • 10.3.8.3. Global Harmonisation Will Improve Compliance
  • 10.4. Trends in Outsourcing Partnerships 2016-2027
    • 10.4.1. Big Pharma and Outsourced Manufacturing
    • 10.4.2. Small and Virtual Pharma Companies
    • 10.4.3. How Will Biotech Funding Impact the Pharma Contract Manufacturing Industry to 2027?

11. Conclusions

  • 11.1. The World Pharmaceutical Contract Manufacturing Market
  • 11.2. Outlook for the Market to 2027
    • 11.2.1. Rising Demand for High Value Services 2016-2027
    • 11.2.2. Demand Will Be Highest Among Developed-Market Clients
  • 11.3. Which New Technologies Will Stimulate Demand to 2027?

Appendices

  • Visiongain's Bespoke Research Service
  • Associated Visiongain Reports
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Visiongain Report Evaluation Form

List of Tables

  • Table 1.1: Pharmaceutical Contract Manufacturing Market: Overall Market and Revenue Forecasts by Sector ($bn), 2015-2027
  • Table 1.2: Currency Exchange Rates
  • Table 3.1: Pharma Contract Manufacturing World Market Revenue ($bn), Annual Growth (%), CAGR (%), 2012-2016
  • Table 3.2: Pharma Contract Manufacturing Market: Revenue ($bn) and Market Share (%) by Sector, 2016
  • Table 3.3: Pharmaceutical Contract Manufacturing Market: Overall Market Forecasts by Sector, Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2027
  • Table 3.4: Pharma Contract Manufacturing Market: Submarket Shares (%), 2014-2020
  • Table 3.5: Pharma Contract Manufacturing Market: Submarket Shares (%), 2021-2027
  • Table 3.6: Other Services Submarket Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2027
  • Table 4.1: Contract API Manufacturing Submarket Revenue ($bn), Annual Growth (%), CAGR (%), 2012-2016
  • Table 4.2: Contract API Manufacturing Submarket: Revenue ($bn) and Submarket Share (%) by Sector, 2016
  • Table 4.3: Contract API Manufacturing Submarket: Overall Submarket Forecasts by Sector, Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2027
  • Table 4.4: Contract API Manufacturing Submarket Shares (%), 2014-2020
  • Table 4.5: Contract API Manufacturing Submarket Shares (%), 2021-2027
  • Table 4.6: Contract API Manufacturing Submarket: Drivers and Restraints, 2016-2027
  • Table 4.7: Contract Generic API Manufacturing Submarket Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2027
  • Table 4.8: Contract Generic API Manufacturing Submarket: Drivers and Restraints, 2016-2027
  • Table 4.9: Contract HPAPI Manufacturing Submarket Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2027
  • Table 4.10: Contract HPAPI Manufacturing Submarket: Drivers and Restraints, 2016-2027
  • Table 5.1: Contract FDF Manufacturing Submarket Revenue ($bn), Annual Growth (%), 2012-2016
  • Table 5.2: Contract FDF Manufacturing Submarket: Revenue ($bn) and Submarket Share (%) by Sector, 2016
  • Table 5.3: Contract FDF Manufacturing Submarket: Overall Submarket Forecasts by Sector, Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2027
  • Table 5.4: Contract FDF Manufacturing Submarket: Segment Shares (%), 2014-2020
  • Table 5.5: Contract FDF Manufacturing Submarket: Segment Shares (%), 2021-2027
  • Table 5.6: Contract FDF Manufacturing Submarket: Drivers and Restraints, 2016-2027
  • Table 5.7: Contract Solid Dosage Manufacturing Submarket Forecast, Revenue ($bn), Annual Growth (%), CAGR (%) 2015-2027
  • Table 5.8: Contract Solid Dosage Manufacturing Submarket: Drivers and Restraints, 2016-2027
  • Table 5.9: Contract Injectable Dosage Manufacturing Submarket Forecast, Revenue ($bn), Annual Growth (%), CAGR (%) 2015-2027
  • Table 5.10: Contract Injectable Dosage Manufacturing Submarket: Drivers and Restraints, 2016-2027
  • Table 5.11: Selected ADCs in Development, 2016
  • Table 5.12: Selected CMOs Investing in ADC Manufacturing Capacity, 2015
  • Table 6.1: Pharma Contract Manufacturing Market: Revenues ($bn) and Market Shares (%) by Region, 2016
  • Table 6.2: Pharma Contract Manufacturing Market: Regional Forecasts, Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2027
  • Table 6.3: Pharmaceutical Contract Manufacturing Market: Developed-Market Shares (%), 2014-2020
  • Table 6.4: Pharmaceutical Contract Manufacturing Market: Developed-Market Shares (%), 2021-2027
  • Table 6.5: GDUFA: Annual Fees for Domestic and Foreign Manufacturing Sites, 2015-2016
  • Table 6.6: US Pharma Contract Manufacturing: Market Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2027
  • Table 6.7: EU Pharma Contract Manufacturing Market: Revenue ($bn) and Market Share (%) by Leading Country, 2014
  • Table 6.8: EU Pharma Contract Manufacturing Market: Revenue ($bn) and Market Share (%) by Leading Country, 2015
  • Table 6.9: EU Pharma Contract Manufacturing Market: Revenue ($bn) and Market Share (%) by Leading Country, 2016
  • Table 6.10: EU5 Pharma Contract Manufacturing Market: National Market Forecasts, Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2027
  • Table 6.11: German Pharma Contract Manufacturing: Market Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2027
  • Table 6.12: Selected French Manufacturing Site Acquisitions, 2009-2013
  • Table 6.13: French Pharma Contract Manufacturing: Market Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2027
  • Table 6.14: Italian Pharma Contract Manufacturing: Market Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2027
  • Table 6.15: Spanish Pharma Contract Manufacturing: Market Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2027
  • Table 6.16: UK Pharma Contract Manufacturing: Market Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2027
  • Table 6.17: Japanese Pharma Contract Manufacturing: Market Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2027
  • Table 7.1: Pharma Contract Manufacturing Market: Emerging Market Revenue ($bn) and Market Share (%) by Top Country, 2016
  • Table 7.2: Pharma Contract Manufacturing Market: Leading Emerging Market Forecasts ($bn), Annual Growth (%), CAGR (%), 2015-2027
  • Table 7.3: Pharma Contract Manufacturing Market: Emerging-Market Shares (%), 2014-2020
  • Table 7.4: Pharma Contract Manufacturing Market: Emerging-Market Shares (%), 2021-2027
  • Table 7.5: Chinese Pharma Contract Manufacturing: Market Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2027
  • Table 7.6: Indian Pharma Contract Manufacturing: Market Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2027
  • Table 7.7: Brazilian Pharma Contract Manufacturing: Market Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2027
  • Table 7.8: Russian Pharma Contract Manufacturing: Market Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2027
  • Table 7.9: South Korean Pharma Contract Manufacturing: Market Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2027
  • Table 8.1: Pharma Contract Manufacturing Market: Revenue ($bn) and Market Share (%) by Top Company, 2014
  • Table 8.2: Catalent: Revenue ($bn), Annual Growth (%), CAGR (%), 2010-2016
  • Table 8.3: Lonza Custom Manufacturing: Revenue ($bn), Annual Growth (%), CAGR (%), 2009-2015
  • Table 8.4: Lonza Custom Manufacturing: Revenue ($bn), Annual Growth (%), H1 2014-H1 2015
  • Table 8.5: DSP: Pharmaceutical Biotech Manufacturing Revenue ($bn), Annual Growth (%), CAGR (%), 2011-2014
  • Table 8.6: DPx and DSP: Q3 Revenue ($bn), 2014-2015
  • Table 8.7: Teva: Revenue ($bn), Annual Growth (%), CAGR (%), 2009-2015
  • Table 8.8: Teva API Revenue ($bn), Annual Growth (%), Q3 2014-Q3 2015
  • Table 8.9: Boehringer Ingelheim BioXcellence: Revenue ($bn), Annual Growth (%), CAGR (%), 2010-2015
  • Table 8.10: Famar: Revenue ($bn), Annual Growth (%), CAGR (%), 2011-2014
  • Table 9.1: Pharma Contract Manufacturing Market Strengths and Weaknesses: CMO Perspective, 2016-2027
  • Table 9.2: Pharma Contract Manufacturing Market Opportunities and Threats: CMO Perspective, 2016-2027
  • Table 9.3: Pharma Contract Manufacturing Market: STEP Analysis, 2016-2027
  • Table 9.4: Selected Lyophilisation Service Providers, 2016
  • Table 9.5: Lyophilisation vs. Spray Drying: A Comparison, 2016
  • Table 9.6: Selected Orphan Drug Prices, 2014
  • Table 9.7: Selected Biological Manufacturing Expansion, 2011-2016
  • Table 9.8: Selected EU-Approved Biosimilars: Manufacturers and Companies, 2016
  • Table 9.9: Selected CMOs Growing Faster than the Market, 2007-2012
  • Table 9.10: Regional Market Expansion, 2010-2016
  • Table 10.1: Pharma Contract Manufacturing Market Strengths and Weaknesses: Client Perspective, 2016-2027
  • Table 10.2: Pharma Contract Manufacturing Market Opportunities and Threats: Client Perspective, 2016-2027
  • Table 10.3: Benefits and Risks to Outsourcing Pharma Manufacturing, 2016
  • Table 10.4: ICH Guidelines: Key Facts and Adoption, 2000-2014
  • Table 12.1: Pharma Contract Manufacturing Market: Revenue ($bn), CAGR (%), and Market Share (%) by Sector, 2014, 2020 and 2027
  • Table 12.2: Pharma Contract Manufacturing Market: Revenue ($bn), CAGR (%), and Market Share (%) by Region, 2014, 2020 and 2027

List of Figures

  • Figure 1.1: Global Pharmaceutical Contract Manufacturing Market Segmentation Overview, 2016
  • Figure 2.1: Selected Services Offered by CMOs, 2016
  • Figure 2.2: Major Trends Affecting Pharma Contract Manufacturing Revenue Growth, 2016-2027
  • Figure 3.1: Pharmaceutical Contract Manufacturing Market Revenue ($bn), 2012-2014
  • Figure 3.2: Pharmaceutical Contract Manufacturing Market Revenue ($bn), 2012-2016
  • Figure 3.3: Pharma Contract Manufacturing: Market Share (%) by Sector, 2016
  • Figure 3.4: Pharmaceutical Contract Manufacturing Market: Overall Market Forecast, Revenue ($bn), 2015-2027
  • Figure 3.5: Pharma Contract Manufacturing Market: Submarket Shares (%), 2020
  • Figure 3.6: Pharma Contract Manufacturing Market: Submarket Shares (%), 2027
  • Figure 3.7: Pharma Contract Manufacturing Market: Drivers, 2016-2027
  • Figure 3.8: Pharma Contract Manufacturing Market: Restraints, 2016-2027
  • Figure 3.9: Other Services Submarket Forecast, Revenue ($bn), 2015-2027
  • Figure 4.1: Contract API Manufacturing Submarket Revenue ($bn), 2012-2016
  • Figure 4.2: Contract API Manufacturing Submarket: Segment Shares (%) by Sector, 2016
  • Figure 4.3: Contract API Manufacturing Submarket Forecast, Revenue ($bn), 2015-2027
  • Figure 4.4: Contract API Manufacturing Submarket: Segment Shares (%), 2020
  • Figure 4.5: Contract API Manufacturing Submarket: Segment Shares (%), 2027
  • Figure 4.6: Contract Generic API Manufacturing Submarket Forecast, Revenue ($bn), 2015-2027
  • Figure 4.7: Contract HPAPI Manufacturing Submarket Forecast, Revenue ($bn), 2015-2027
  • Figure 5.1: Contract FDF Manufacturing Submarket Revenue ($bn), 2012-2016
  • Figure 5.2: Contract FDF Manufacturing Submarket: Segment Shares (%) by Sector, 2016
  • Figure 5.3: Contract FDF Manufacturing Submarket Forecast, Revenue ($bn), 2015-2027
  • Figure 5.4: Contract FDF Manufacturing Submarket: Segment Shares (%), 2020
  • Figure 5.5: Contract FDF Manufacturing Submarket: Segment Shares (%), 2027
  • Figure 5.6: Contract Solid Dosage Manufacturing Submarket Forecast ($bn), 2015-2027
  • Figure 5.7: Contract Injectable Dosage Manufacturing Submarket Forecast, Revenue ($bn), 2015-2027
  • Figure 6.1: Pharma Contract Manufacturing Market: Share (%) by Region, 2016
  • Figure 6.2: Pharmaceutical Contract Manufacturing Market: Share (%) by Region, 2020
  • Figure 6.3: Pharmaceutical Contract Manufacturing Market: Share (%) by Region, 2027
  • Figure 6.4: US Pharma Contract Manufacturing: Market Forecast, Revenue ($bn), 2015-2027
  • Figure 6.5: EU5 Pharma Contract Manufacturing Market: Share (%) by Country, 2014
  • Figure 6.6: EU5 Pharma Contract Manufacturing Market: Share (%) by Country, 2015
  • Figure 6.7: EU5 Pharma Contract Manufacturing Market: Share (%) by Country, 2016
  • Figure 6.8: EU5 Pharma Contract Manufacturing Market: Share (%) by Country, 2020
  • Figure 6.9: EU5 Pharma Contract Manufacturing Market: Share (%) by Country, 2027
  • Figure 6.10: EU5 Pharma Contract Manufacturing Market: National Market Forecast, Revenue ($bn), 2015-2027
  • Figure 6.11: German Pharma Contract Manufacturing: Market Forecast, Revenue ($bn), 2015-2027
  • Figure 6.12: French Pharma Contract Manufacturing: Market Forecast, Revenue ($bn), 2015-2027
  • Figure 6.13: Italian Pharma Contract Manufacturing: Market Forecast, Revenue ($bn), 2015-2027
  • Figure 6.14: Spanish Pharma Contract Manufacturing: Market Forecast, Revenue ($bn), 2015-2027
  • Figure 6.15: UK Pharma Contract Manufacturing: Market Forecast, Revenue ($bn), 2015-2027
  • Figure 6.16: Japanese Pharma Contract Manufacturing: Market Forecast, Revenue ($bn), 2015-2027
  • Figure 7.1: Pharma Contract Manufacturing Market: Emerging Market Share (%) by Top Country, 2016
  • Figure 7.2: Pharma Contract Manufacturing Market: Emerging Market Share (%) by Top Country, 2020
  • Figure 7.3: Pharma Contract Manufacturing Market: Emerging Market Share (%) by Top Country, 2027
  • Figure 7.4: harma Contract Manufacturing Market: Emerging Market Share (%) by Top Country, 2014, 2020 and 2027
  • Figure 7.5: Chinese Pharma Contract Manufacturing: Market Forecast, Revenue ($bn), 2015-2027
  • Figure 7.6: Indian Pharma Contract Manufacturing: Market Forecast, Revenue ($bn), 2015-2027
  • Figure 7.7: razilian Pharma Contract Manufacturing: Market Forecast, Revenue ($bn), 2015-2027
  • Figure 7.8: Russian Pharma Contract Manufacturing: Market Forecast, Revenue ($bn), 2015-2027
  • Figure 7.9: South Korean Pharma Contract Manufacturing: Market Forecast, Revenue ($bn), 2015-2027
  • Figure 8.1: Pharma Contract Manufacturing: Market Share (%) by Top Company, 2014
  • Figure 8.2: Catalent: Revenue ($bn), 2010-2016
  • Figure 8.3: Lonza Custom Manufacturing: Revenue ($bn), 2009-2016
  • Figure 8.4: DSP: Pharmaceutical Biotech Manufacturing Revenue ($bn), 2011-2015
  • Figure 8.5: Teva: Revenue ($bn), 2009-2015
  • Figure 8.6: Boehringer Ingelheim BioXcellence: Revenue ($bn), 2010-2015
  • Figure 8.7: Famar: Revenue ($bn), 2011-2014
  • Figure 10.1: Overview of Approved ICH Manufacturing Guidelines, 2016
  • Figure 12.1: Pharma Contract Manufacturing Market: Revenue ($bn) by Sector, 2014, 2020 and 2027
  • Figure 12.2: Pharma Contract Manufacturing Market: Revenue ($bn) by Region, 2014, 2020 and 2027

Companies Listed

  • AbbVie
  • Actavis
  • ADC Biotechnology
  • Aegerion Pharmaceuticals
  • Aenova Group
  • Aesica Pharma
  • Agência Nacional de Vigilância Sanitária (ANVISA)
  • Agensys
  • Agila Specialties
  • Ajinomoto Althea Inc
  • Alexion Pharmaceuticals
  • Almac Group
  • Althea Technologies
  • AMRI (Albany Molecular Research Inc)
  • API Corporation (APIC)
  • Asociación Española de Fabricantes de Productos de Química Fina (AFAQUIM)
  • Aspen Pharmacare
  • Associação Brasileira da Indústria Farmoquímica e de Insumos Farmacêuticos (ABIQUIFI)
  • Association of British Pharmaceutical Industry (ABPI)
  • Astellas
  • AstraZeneca
  • Banner Life Sciences
  • Banner Pharmacaps
  • Baring Private Equity Asia
  • Bausch & Lomb
  • Bayer Healthcare
  • Ben Venue Laboratories
  • Bend Research
  • Biogen Idec
  • BioIndustry Association (BIA)
  • Biotest
  • Blackstone Group
  • Boehringer Ingelheim
  • Boehringer Ingelheim BioXcellence
  • Bristol-Myers Squibb Company
  • Bushu Pharmaceuticals
  • Cambrex
  • Cambridge Major Laboratories
  • Catalent Pharma Solutions
  • Cedarburg Hauser
  • Cell Therapy Catapult
  • Celldex Therapeutics
  • Celltrion
  • Cenexi
  • Central Drugs Standard Control Organization (CDSCO)
  • Chemisch-Pharmazeutisches Laboratorium Ravensburg
  • Chemtrix
  • China FDA (CFDA)
  • Cipla
  • Cook Pharmica
  • CordenPharma
  • CTC Bio
  • Daito Pharmaceutical
  • Delpharm
  • Department of Health and Family Welfare
  • Development and Reform Commission (NDRC)
  • Dishman Pharmaceuticals
  • DPx Fine Chemicals
  • DPx Holdings B.V.
  • Dr. Reddy's Laboratories
  • DSP (DSM Sinochem Pharmaceuticals)
  • Eisai
  • Eli Lilly
  • Esteve Quimica
  • European Commission
  • European Medicines Agency (EMA)
  • Euticals
  • Evonik Degussa
  • Famar
  • Fareva
  • Food and Drug Administration (US FDA)
  • FUJIFILM Diosynth Biotechnologies,
  • Gallus Biopharmaceutical, LLC.
  • G-CON
  • GEA Pharma-Systems
  • Genentech
  • GlaxoSmithKline (GSK)
  • Granules India
  • Haupt Pharma
  • Hexal
  • Hospira
  • Hospira One2One
  • ImmunoGen
  • Immunomedics
  • Indian Drug Manufacturer's Association (IDMA)
  • Indian Pharmaceutical Alliance
  • Innovent Biologics
  • International Society of Pharmaceutical Engineering (IPSE)
  • IRIX Pharmaceuticals
  • Janssen
  • JK Pharmaceutical
  • Johnson & Johnson
  • Knowledge Transfer Network (KTN)
  • Korea Food and Drug Administration (KFDA)
  • Korea Pharmaceutical Manufacturer's Association (KPMA)
  • Lonza
  • Lupin
  • Marinopoulos Group
  • Matrix Laboratories
  • Medice
  • Medichem
  • Medicines and Healthcare Products Regulatory Agency (MHRA)
  • Medicines Manufacturing Industry Partnership (MMIP)
  • Merck & Co.
  • Micron Technologies
  • Millennium
  • Ministry of Health (MOH)
  • Ministry of Health, Labor and Welfare (MHLW)
  • Ministry of Industry and Information Technology (MIIT)
  • Mitsui & Co
  • Momenta Pharmaceuticals
  • Mylan
  • Neuland Laboratories
  • NICE Insight
  • NPS Pharmaceuticals
  • Nycomed
  • Orchid Chemicals & Pharmaceuticals
  • Oxford Biomedica
  • Patheon
  • Patheon Biologics
  • Pfizer
  • Pharmaceutical and Medical Devices Agency (PMDA)
  • Pharmapak Technologies
  • Piramal Pharma Solutions
  • Progenics
  • Quintiles
  • Recepta Biopharma
  • Recipharm
  • Redwood Bioscience
  • Rentschler Biotechnologie
  • Roche
  • Royal DSM
  • SAFC
  • SafeBridge
  • Samsung Bioepis
  • Samsung BioLogics
  • Sandoz
  • Sanofi
  • Seattle Genetics
  • Shandong Xinhua
  • ShangPharma
  • Shire
  • Siegfried AG
  • Sigmar Italia
  • SMS Pharmaceuticals
  • Solvias AG
  • Speedel
  • Stada
  • Stem CentRx
  • Stevenage Bioscience Catalyst
  • Takeda
  • Temmler Group
  • Teva API
  • Thermo Fisher Scientific
  • UMN Pharma
  • UNIGEN
  • Valeant Pharmaceuticals
  • Valerion Therapeutics, LLC.
  • Vetter Pharma-Fertigung GmbH
  • Vivante GMP Solutions
  • West Pharmaceutical Services
  • World Health Organization (WHO)
  • WuXi PharmaTech
  • Zhangjiang Biotech & Pharmaceutical Base Company
  • Zhejiang Jiang Yuan Tang Biotechnology
Back to Top